- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Pacira BioSciences, Inc.(PCRX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PCRX
11/13/2026: PCRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Pacira BioSciences is a specialty pharmaceutical company known for its non-opioid pain management products, most notably EXPAREL, which is widely used in surgical settings. The company has a leading position in the niche for extended-release local anesthetics, providing a key alternative to traditional opioid use. Its growth story hinges on successfully expanding the reach of its newer products, ZILRETTA and iovera°, to diversify revenue. However, the company faces significant risks from generic competition, ongoing patent litigation, and execution challenges in the outpatient market. This stock may suit investors focused on the biotechnology sector who are comfortable with the inherent volatility linked to clinical and regulatory developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company faces a maturing primary product, making growth contingent on successful pipeline execution and expansion. |
| Momentum investor | Weak fit | Stock performance is currently driven by specific clinical and legal catalysts rather than sustained positive technical momentum. |
| Value investor | Mixed fit | Valuation may appear attractive following recent volatility, but depends heavily on the sustainability of patent protections. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on capital reinvestment. |
| Low-risk investor | Weak fit | High sensitivity to regulatory and patent litigation risks makes this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock often reacts sharply to patent litigation updates and clinical trial results. |
| Valuation risk | Medium / high | Market pricing is sensitive to the long-term competitive landscape for the core EXPAREL franchise. |
| Competition risk (generic) | High | Generic bupivacaine formulations pose a constant threat to pricing power and market share. |
| Business quality | Medium | While the product line is specialized, dependency on a narrow range of assets creates concentration risk. |
| Dividend income | Low / none | There is no income stream for investors, limiting appeal for income-oriented strategies. |
| Execution risk | Medium / high | Successful expansion of the iovera° and ZILRETTA franchises is critical for future diversification. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.46B USD | Price to earnings Ratio 39.2 | 1Y Target Price 33.57 |
Price to earnings Ratio 39.2 | 1Y Target Price 33.57 | ||
Volume (30-day avg) 2.2M shares | Beta 0.22 | 52 Weeks Range 18.80 - 36.67 | Updated Date 11/13/2026 |
52 Weeks Range 18.80 - 36.67 | Updated Date 11/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.93 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 66.7%
- Active BUY / eligible
- 8 / 12
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -19.36% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Postsurgical Pain Management | Primary revenue from EXPAREL sales to hospitals and surgery centers. | The vast majority of revenue comes from hospitals using EXPAREL to reduce patient opioid usage after surgery. |
| Joint and Orthopedic Pain | Revenue from ZILRETTA and iovera° system sales. | This segment is smaller but focuses on the growing market for long-term management of osteoarthritis and joint pain. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-11-05 | When Before Market | Estimate 0.47 | Actual 0.46 |
Profitability
Profit Margin 5.08% | Operating Margin (TTM) 4% |
Management Effectiveness
Return on Assets (TTM) 1.49% | Return on Equity (TTM) 5.24% |
Valuation
Trailing PE 39.2 | Forward PE 9.9 | Enterprise Value 1.50B | Price to Sales(TTM) 1.96 |
Enterprise Value 1.50B | Price to Sales(TTM) 1.96 | ||
Enterprise Value to Revenue 2.02 | Enterprise Value to EBITDA 11.35 | Shares Outstanding 39.91M | Shares Floating 39.37M |
Shares Outstanding 39.91M | Shares Floating 39.37M | ||
Percent Insiders 1.33 | Percent Institutions 109.79 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

